Target intelligence / Profile preview

Proteasome 26S subunit ATPase 5 (PSMC5)

Target
PSMC5
Molecular classification
Enzyme, AAA+ ATPase, Proteasome subunit, Component of the 19S regulatory particle of the 26S proteasome complex
01

Overview

Proteasome 26S subunit ATPase 5 (PSMC5), also known as 26S proteasome regulatory subunit 8 or SUG1, is an ATPase component of the 19S regulatory particle of the 26S proteasome complex. The 26S proteasome is essential for ubiquitin-dependent protein degradation in eukaryotic cells. PSMC5, a member of the AAA+ ATPase family, is involved in unfolding and translocation of ubiquitinated proteins into the 20S core particle for degradation. It plays key roles in cellular protein quality control, cell cycle regulation, apoptosis, antigen processing for immune presentation, and regulation of transcription through interactions with transcription factors and nuclear receptors. Dysfunction of the proteasome system, including defects in PSMC5, has been implicated in cancer, neurodegenerative diseases, and rare genetic syndromes. While broadly targeted by proteasome inhibitors in cancer therapy, PSMC5 itself has not yet been selectively targeted by small molecules.

Other names
26S proteasome regulatory subunit 8SUG1TRIP1p45/SUGTBP10p45S8RPT626S proteasome AAA-ATPase subunit RPT6Proteasome subunit p45Thyroid hormone receptor-interacting protein 1MSUG1 proteinTat-binding protein homolog 10proteasome (prosome, macropain) 26S subunit, ATPase 5testicular tissue protein Li 149thyroid receptor interactor 1
02

Mechanism of action

Proteasome inhibitors bind to and inhibit proteolytic activity, preventing degradation of ubiquitinated proteins, leading to apoptosis especially in rapidly dividing cells

03

Biological functions

Protein degradation (ubiquitin-dependent proteolysis)Protein homeostasisCell cycle regulationApoptosisDNA damage repairTranscriptional regulationAntigen processing (MHC class I peptide generation)Signal transduction
04

Disease associations

CancerInflammationNeurodegenerative diseaseGenetic syndromes (e.g., Arthrogryposis, distal, type 6; Ogden syndrome)
05

Safety considerations

Proteasome inhibition causes toxicity to normal cellsSide effects: peripheral neuropathy, myelosuppression, infectionsResistance emergence in long-term therapy
06

Interacting drugs

Bortezomib (non-selective, targets 26S proteasome complex)

2 more in the full profile.

07

Biomarkers

Proteasome activity (general marker in cancers and therapy response)Ubiquitinated protein levels (indirect marker)

Beyond the preview

Go deeper on Proteasome 26S subunit ATPase 5 (PSMC5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome 26S subunit ATPase 5 (PSMC5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call